Abacha Yabalu Z, Forkuo Arnold Donkor, Gbedema Stephen Y, Mittal Nimisha, Ottilie Sabine, Rocamora Frances, Winzeler Elizabeth A, van Schalkwyk Donelly A, Kelly John M, Taylor Martin C, Reader Janette, Birkholtz Lyn-Marie, Lisgarten David R, Cockcroft Jeremy K, Lisgarten John N, Palmer Rex A, Talbert Rosemary C, Shnyder Steven D, Wright Colin W
School of Pharmacy and Medical Sciences, University of Bradford, Bradford, United Kingdom.
Department of Pharmacognosy, Faculty of Pharmacy, University of Maiduguri, Maiduguri, Nigeria.
Front Pharmacol. 2022 Apr 26;13:875647. doi: 10.3389/fphar.2022.875647. eCollection 2022.
The prospect of eradicating malaria continues to be challenging in the face of increasing parasite resistance to antimalarial drugs so that novel antimalarials active against asexual, sexual, and liver-stage malaria parasites are urgently needed. In addition, new antimalarials need to be affordable and available to those most in need and, bearing in mind climate change, should ideally be sustainable. The West African climbing shrub is used traditionally for the treatment of malaria; its principal alkaloid, cryptolepine (), has been shown to have antimalarial properties, and the synthetic analogue 2,7-dibromocryptolepine () is of interest as a lead toward new antimalarial agents. Cryptolepine () was isolated using a two-step Soxhlet extraction of roots, followed by crystallization (yield 0.8% calculated as a base with respect to the dried roots). Semi-synthetic 7-bromo- (), 7, 9-dibromo- (), 7-iodo- (), and 7, 9-dibromocryptolepine () were obtained in excellent yields by reaction of with -bromo- or -iodosuccinimide in trifluoroacetic acid as a solvent. All compounds were active against , but showed the most selective profile with respect to Hep G2 cells: (chloroquine-resistant strain K1), IC = 0.25 µM, SI = 113; late stage, gametocytes, IC = 2.2 µM, SI = 13; liver stage, sporozoites IC = 6.13 µM, SI = 4.6. Compounds - were also active against the emerging zoonotic species with being the most potent (IC = 0.11 µM). In addition, - potently inhibited at nM concentrations and good selectivity with again being the most selective (IC = 59 nM, SI = 478). These compounds were also cytotoxic to wild-type ovarian cancer cells as well as adriamycin-resistant and, except for , cisplatin-resistant ovarian cancer cells. In an acute oral toxicity test in mice, - did not exhibit toxic effects at doses of up to 100 mg/kg/dose × 3 consecutive days. This study demonstrates that may be utilized as a sustainable source of novel compounds that may lead to the development of novel agents for the treatment of malaria, African trypanosomiasis, and cancer.
面对疟原虫对抗疟药物的耐药性不断增强,根除疟疾的前景依然充满挑战,因此迫切需要对无性、有性和肝期疟原虫均有效的新型抗疟药。此外,新型抗疟药需要价格亲民,让最有需求的人能够获得,并且考虑到气候变化,理想情况下应具备可持续性。西非攀缘灌木传统上用于治疗疟疾;其主要生物碱隐色草碱()已被证明具有抗疟特性,其合成类似物2,7 - 二溴隐色草碱()作为新型抗疟药的先导化合物受到关注。隐色草碱()是通过对根进行两步索氏提取,然后结晶得到的(以碱计相对于干燥根的产率为0.8%)。半合成的7 - 溴 - ()、7,9 - 二溴 - ()、7 - 碘 - ()和7,9 - 二溴隐色草碱()通过在三氟乙酸作为溶剂中使与 - 溴 - 或 - 碘琥珀酰亚胺反应,以优异的产率获得。所有化合物对均有活性,但在对Hep G2细胞的选择性方面表现最佳:(氯喹耐药株K1),IC = 0.25 μM,SI = 113;晚期,配子体,IC = 2.2 μM,SI = 13;肝期,子孢子IC = 6.13 μM,SI = 4.6。化合物 - 对新出现的人畜共患病物种也有活性,其中最有效(IC = 0.11 μM)。此外, - 在纳摩尔浓度下能有效抑制,且选择性良好,同样是最具选择性的(IC = 59 nM,SI = 478)。这些化合物对野生型卵巢癌细胞以及阿霉素耐药和除之外的顺铂耐药卵巢癌细胞也具有细胞毒性。在小鼠急性口服毒性试验中, - 在高达100 mg/kg/剂量×连续3天的剂量下未表现出毒性作用。这项研究表明,可作为新型化合物的可持续来源,这些化合物可能会促使开发出用于治疗疟疾、非洲锥虫病和癌症的新型药物。